TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33716072

Group type: EXPERIMENTAL
Intervention: In vitro fertilization with preimplantation genetic testing for aneuploidy and uterus transplantation followed by frozen embryo transfer.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single embryo transfer of a warmed, good-quality, euploid, expanded blastocyst after successful uterus transplantation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first embryo transfer.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first clinical pregnancy.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first live birth.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total live births after successful uterus transplantation and embryo transfer.
Number of subjects: 20
Study: 33716134

Group type: EXPERIMENTAL
Intervention: Patient-reported opioid use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time electronic opioid use tracking
Number of subjects: 0
Study: 33716499

Group type: EXPERIMENTAL
Intervention: Without anticholinergic
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: With anticholinergic
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: With opioids
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: With dexmedetomidine
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: With IV dexamethasone
Number of subjects: 2527

Group type: COMPARATOR
Intervention: Various anesthetic agents
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Inhalational agents
Number of subjects: 2527
Study: 33716695

Group type: EXPERIMENTAL
Intervention: Random training paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Block training paradigm
Number of subjects: 0
Study: 33716817

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment, specific details not available.
Number of subjects: 0
Study: 33716824

Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33716889

Group type: EXPERIMENTAL
Intervention: Non-immersive Virtual Reality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Intervention
Number of subjects: 0
Study: 33716934

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear Incision Technique With Soft Tissue Preservation
Number of subjects: 0
Study: 33716945

Group type: EXPERIMENTAL
Intervention: BETACONNECT
Number of subjects: 0
Study: 33716948

Group type: EXPERIMENTAL
Intervention: Arm-Hand Boost Therapy during inpatient stroke rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study: 33717057

Group type: EXPERIMENTAL
Intervention: BCMA-directed Chimeric Antigen Receptor T cells (CART) therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 1
Study: 33717176

Group type: EXPERIMENTAL
Intervention: Placental malaria vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33717535

Group type: EXPERIMENTAL
Intervention: Easyhaler (EH)
Number of subjects: 397
Study: 33718212

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) for CRC screening
Number of subjects: 3165

Group type: EXPERIMENTAL
Intervention: Serum prostate specific antigen (PSA) and Prostate Health Index (PHI) for male PC screening
Number of subjects: 3165

Group type: EXPERIMENTAL
Intervention: Mammogram (MMG) for female BC screening
Number of subjects: 3165
Study: 33718225

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study: 33718228

Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination with peptide CALRLong36, 15 vaccines administered
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination with peptide CALRLong36
Number of subjects: 10
Study: 33718234

Group type: EXPERIMENTAL
Intervention: Novel conditioning regimen
Number of subjects: 0
Study: 33718294

Group type: EXPERIMENTAL
Intervention: Executive Function Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33718302

Group type: EXPERIMENTAL
Intervention: SIRS-defined sepsis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-adapted SOFA-defined sepsis
Number of subjects: 0
Study: 33718425

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin-sensitive group
Number of subjects: 30
Study: 33718451

Group type: EXPERIMENTAL
Intervention: High TMAO group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Low TMAO group
Number of subjects: 179
Study: 33719441

Group type: EXPERIMENTAL
Intervention: GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor, dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implied as untreated or standard treatment.
Number of subjects: 0
Study: 33719492

Group type: EXPERIMENTAL
Intervention: Electroanatomic ratios (QRSd indexed for height or left ventricular end-diastole volume)
Number of subjects: 4899
Study: 33719721

Group type: EXPERIMENTAL
Intervention: PH FDC SC (subcutaneous injection)
Number of subjects: 500

Group type: COMPARATOR
Intervention: IV pertuzumab plus trastuzumab
Number of subjects: 500
Study: 33719728

Group type: EXPERIMENTAL
Intervention: Dual-task walking in people with PD MCI
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dual-task walking in people with PD non-MCI
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cognitive status influence on dual-task costs
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonmotor experiences of daily living
Number of subjects: 93

Group type: COMPARATOR
Intervention: TUG-cog (Timed Up and Go cognitive)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Overall dual-task costs across gait domains
Number of subjects: 93
Study: 33720032

Group type: EXPERIMENTAL
Intervention: eVisits for sore throat
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: eVisits for respiratory symptoms
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: eVisits for dysuria
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: eVisits for sore throat (guideline-recommended antibiotics)
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: eVisits for respiratory symptoms (guideline-recommended antibiotics)
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: eVisits for dysuria (guideline-recommended antibiotics)
Number of subjects: 3847
Study: 33720067

Group type: EXPERIMENTAL
Intervention: Nonimmunological stromal targeting strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor ECM components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor ECM
Number of subjects: 0
Study: 33720068

Group type: EXPERIMENTAL
Intervention: NTRK inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RET inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple kinase inhibitors
Number of subjects: 0
Study: 33720071

Group type: EXPERIMENTAL
Intervention: Pathway group (detailed patient education, long-acting nerve block with bupivacaine and dexamethasone, preemptive multimodal analgesia)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Pathway group
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study: 33720088

Group type: EXPERIMENTAL
Intervention: Mutated forms of SORL1 micro-haplotype (CAT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Wild-type form of SORL1 micro-haplotype (TTG)
Number of subjects: 86
Study: 33720336

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (CAR T-cell therapy)
Number of subjects: 268
Study: 33720337

Group type: EXPERIMENTAL
Intervention: Rituximab-based therapies (including R-Dox) with maintenance AZT/VGC or interferon
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatments administered at investigator discretion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Concurrent diagnosis of PEL
Number of subjects: 62
Study: 33720354

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study: 33720424

Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks for 3 cycles
Number of subjects: 143
Study: 33720513

Group type: EXPERIMENTAL
Intervention: Microduplication in the 10q26.3 region including part of the INPP5A gene
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phenotyping and genotyping (including CGH-array)
Number of subjects: 3
Study: 33720573

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1023
Study: 33720749

Group type: EXPERIMENTAL
Intervention: Bundled Acupuncture and Yoga Therapy
Number of subjects: 0
Study: 33720906

Group type: EXPERIMENTAL
Intervention: Moderate OSA
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Severe OSA
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: STOP-Bang score of 3-4
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: STOP-Bang score of 5-8
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Increasing neck circumference
Number of subjects: 869

Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 869
Study: 33721209

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 42953

Group type: COMPARATOR
Intervention: LABA/ICS
Number of subjects: 42953
Study: 33721213

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 33721289

Group type: EXPERIMENTAL
Intervention: Anticholinergic Drug Scale (ADS)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Anticholinergic Risk Scale (ARS)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Anticholinergic Cognitive Burden Scale (ACBS)
Number of subjects: 837
Study: 33721377

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among people who never used injecting drugs
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among PWIDs without OAT
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among PWIDs with OAT
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) for recent drug users
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among recent drug users
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) overall
Number of subjects: 336
Study: 33721837

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 1000 IU single dose
Number of subjects: 6
Study: 33721875

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam premedication (N = 749 after matching)
Number of subjects: 1266

Group type: COMPARATOR
Intervention: No midazolam premedication (N = 357 after matching)
Number of subjects: 1266
Study: 33722059

Group type: EXPERIMENTAL
Intervention: Right Ventricular Ejection Fraction (RVEF) measurement
Number of subjects: 7131
Study: 33722066

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33722290

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 3011
Study: 33722295

Group type: EXPERIMENTAL
Intervention: Targeted sequencing of a 91 gene panel (n=67) and whole-exome sequencing (n=30)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 123
Study: 33722305

Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart HR+ wearable device measuring floors climbed, total steps, and total distance travelled for 7 days prior to surgery
Number of subjects: 49
Study: 33722701

Group type: EXPERIMENTAL
Intervention: Chemotherapy including steroids (dexamethasone)
Number of subjects: 270
Study: 33722855

Group type: EXPERIMENTAL
Intervention: OBI-999 (a novel antibody-drug conjugate targeting Globo H)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OBI-999
Number of subjects: 0
Study: 33722860

Group type: EXPERIMENTAL
Intervention: Blue dye method for measuring gut transit time
Number of subjects: 863
Study: 33722961

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System with adjunctive coiling
Number of subjects: 116
Study: 33722996

Group type: EXPERIMENTAL
Intervention: Lateropulsion (pusher syndrome)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Body tilt, pushing, and resistance
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Contralesional visual vertical (VV)
Number of subjects: 220
Study: 33723220

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 min)
Number of subjects: 46
Study: 33723260

Group type: EXPERIMENTAL
Intervention: Personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC) combined with bevacizumab (Bev), cyclophosphamide (Cy), acetylsalicylic acid (ASA), and low-dose interleukin (IL)-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OCDC-Bev-Cy regimen
Number of subjects: 0
Study: 33723462

Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0
Study: 33723507

Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 100 mcg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 200 mcg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 400 mcg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 32
Study: 33723724

Group type: EXPERIMENTAL
Intervention: TAS-117 (16 mg daily for GI cancers; 24 mg on a 4 days on/3 days off schedule for non-GI cancers)
Number of subjects: 13
Study: 33724063

Group type: EXPERIMENTAL
Intervention: Proton MR Spectroscopy in BAT
Number of subjects: 21
Study: 33724066

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 0
Study: 33724366

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of frailty score
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Frailty predicts death one year after elective cardiac surgery test
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons score
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: European System for Cardiac Operative Risk Evaluation
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Frailty assessment added to existing risk scores
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Frailty assessment
Number of subjects: 604
Study: 33724632

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (damoctocog alfa pegol); prophylactic treatment twice weekly, every 5 days or every 7 days for ≥50 exposure days.
Number of subjects: 73
Study: 33724867

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33725199

Group type: EXPERIMENTAL
Intervention: Current and emerging therapies for cardiac amyloidosis
Number of subjects: 0
Study: 33725209

Group type: EXPERIMENTAL
Intervention: Early hypercapnia (defined as an arterial partial pressure of carbon dioxide, PaCO2) present in 39 patients (59.1%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hypocapnia during the monitoring period
Number of subjects: 66
Study: 33725322

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (100, 200, 300 µg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (up to 300 µg)
Number of subjects: 36
Study: 33725363

Group type: EXPERIMENTAL
Intervention: Plasma HMGB1 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6-MWT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: handgrip-strength test (HST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: timed-stands test (TST)
Number of subjects: 100
Study: 33725387

Group type: EXPERIMENTAL
Intervention: Current follow-up schedule with 3-monthly endoscopy and MRI in the first year and 6-monthly thereafter
Number of subjects: 304

Group type: COMPARATOR
Intervention: Hypothetical follow-up schedules
Number of subjects: 304
Study: 33725672

Group type: EXPERIMENTAL
Intervention: Computational approaches to decode grasping force and velocity level from intraneural peripheral signals
Number of subjects: 0
Study: 33725747

Group type: EXPERIMENTAL
Intervention: HIV patients
Number of subjects: 162

Group type: COMPARATOR
Intervention: BC survivors
Number of subjects: 162
Study: 33726776

Group type: EXPERIMENTAL
Intervention: UDI-6 Total Score of 33.33
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: IIQ-7 Total Score of 9.52
Number of subjects: 205
Study: 33726819

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids for critical COVID-19
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Awake self-proning
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Closed suction systems
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prone ventilation (for 16-24 hours per day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Avoiding delay in extubation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Timing of tracheostomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Positive end expiratory pressure titration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Choice of personal protective equipment
Number of subjects: 39
Study: 33726855

Group type: EXPERIMENTAL
Intervention: QbTest protocol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44
Study: 33727121

Group type: EXPERIMENTAL
Intervention: LVAR present (21% of patients, n = 33)
Number of subjects: 155
Study: 33727235

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 1933

Group type: COMPARATOR
Intervention: Other non-invasive oxygen strategy
Number of subjects: 1933
Study: 33727626

Group type: EXPERIMENTAL
Intervention: Current URI symptoms (mild severity)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Presence and severity of URI
Number of subjects: 256
Study: 33727862

Group type: EXPERIMENTAL
Intervention: Sensitive and highly sensitive responders to warfarin
Number of subjects: 2508

Group type: COMPARATOR
Intervention: Normal responders to warfarin
Number of subjects: 2508
Study: 33727901

Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: valsartan (target dose, 160 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 0
Study: 33728434

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted seasonal influenza vaccine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pneumovax23 (PPV23)
Number of subjects: 65
Study: 33728493

Group type: EXPERIMENTAL
Intervention: Laser microgrooved surface (LMS) healing and prosthetic abutments
Number of subjects: 24

Group type: COMPARATOR
Intervention: Machined surface (MS) healing and prosthetic abutments
Number of subjects: 24
Study: 33728546

Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (Q2W) intravenously (IV)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (Q3W) IV
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Cemiplimab (both dosing regimens)
Number of subjects: 548
Study: 33728583

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1522
Study: 33728588

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEK inhibition targeting the RAS-pathway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral HMAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of splicing, CD123/dendritic cell axis, GM-CSF progenitor cell hypersensitivity, JAK/STAT pathway targeting
Number of subjects: 0
Study: 33729162

Group type: COMPARATOR
Intervention: Version 1 of the Consilium Care app
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Version 2 of the Consilium Care app
Number of subjects: 192
Study: 33729164

Group type: EXPERIMENTAL
Intervention: Web-based shared decision-making tool
Number of subjects: 0
Study: 33729165

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA stimulation for 30 minutes per session, 30 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS (brief period of stimulation to mimic sensations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 33729718

Group type: EXPERIMENTAL
Intervention: Checklist for Early Recognition and Treatment of Acute Illness and Injury implementation
Number of subjects: 4256
Study: 33730034

Group type: EXPERIMENTAL
Intervention: Higher perceived social support (measured by FACIT-F) without depressive symptoms
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Higher perceived social support (measured by FACIT-F) with depressive symptoms
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of social support
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1779
Study: 33730173

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33730336

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 11051
Study: 33730360

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-BCMA antibody-drug conjugate (belantamab mafodotin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel targets and constructs (bispecific antibodies against BCMA, GPRC5D, FCRH5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody-based therapy
Number of subjects: 0
Study: 33730422

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 7249

Group type: COMPARATOR
Intervention: No assisted hatching
Number of subjects: 7249